NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2

Suspended

Conditions: Down Syndrome
Recurrent B Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Radiation: 3-Dimensional Conformal Radiation Therapy
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Calaspargase Pegol
Drug: Dexamethasone
Drug: Cytarabine
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Biological: Nivolumab
Drug: Mercaptopurine
Drug: Pegaspargase
Drug: Pegcrisantaspase
Drug: Vincristine Sulfate

First Posted Date: 2020-09-14

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 300

Registration Number: NCT04546399

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 200 locations

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1

Terminated

Conditions: Recurrent Sezary Syndrome
Mycosis Fungoides
Refractory Mycosis Fungoides and Sezary Syndrome
Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
Recurrent Mycosis Fungoides and Sezary Syndrome
Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Recurrent Mycosis Fungoides
Refractory Mycosis Fungoides
Refractory Sezary Syndrome

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Magrolimab
Biological: Mogamulizumab
Procedure: Positron Emission Tomography
Procedure: Punch Biopsy

First Posted Date: 2020-09-09

Last Posted Date: 2024-10-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT04541017

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

and more 15 locations

Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies

Active, not recruiting

Conditions: Prostate Cancer

First Posted Date: 2020-09-09

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 241

Registration Number: NCT04541030

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase 1

Suspended

Conditions: Recurrent Childhood Neuroblastoma
Recurrent Childhood Osteosarcoma
Recurrent Neuroblastoma
Recurrent Osteosarcoma
Refractory Childhood Neuroblastoma
Refractory Childhood Osteosarcoma
Refractory Neuroblastoma
Refractory Osteosarcoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Procedure: Echocardiography Test
Drug: Fludarabine Phosphate
Biological: GD2-CAR-expressing Autologous T-lymphocytes
Procedure: Imaging Procedure
Procedure: Magnetic Resonance Imaging of the Heart
Procedure: Multigated Acquisition Scan
Other: Questionnaire Administration

First Posted Date: 2020-09-07

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 67

Registration Number: NCT04539366

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 3 locations

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2

Terminated

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma
Small Cell/Neuroendocrine

Interventions: Drug: Olaparib
Drug: Durvalumab
Diagnostic Test: EKG
Procedure: Tumor biopsy
Diagnostic Test: CT chest, abdomen and pelvis
Diagnostic Test: MRI chest, abdomen and pelvis

First Posted Date: 2020-09-04

Last Posted Date: 2025-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT04538378

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Phase 2

Withdrawn

Conditions: Metastatic HPV-16 Positive Squamous Cell Anal Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Drug: Pembrolizumab (KEYTRUDA(R))
Biological: Individual Patient TCR-Transduced PBL

First Posted Date: 2020-09-03

Last Posted Date: 2021-02-01

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04536922

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

Phase 2

Completed

Conditions: Gastric Cancer
Gastric Neoplasms
Gastric Adenocarcinoma

Interventions: Device: Cellvizio (Registered trademark)Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
Device: Olympus GIF 190 endoscope

First Posted Date: 2020-09-02

Last Posted Date: 2025-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 195

Registration Number: NCT04535414

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Phase 1

Active, not recruiting

Conditions: Advanced Colorectal Carcinoma
Metastatic Digestive System Carcinoma
Stage IV Colorectal Cancer AJCC v8
Advanced Gastric Carcinoma
Clinical Stage IV Gastric Cancer AJCC v8
Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Gastroesophageal Junction Adenocarcinoma
Stage III Colorectal Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging
Drug: Elimusertib
Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Drug: Leucovorin Calcium

First Posted Date: 2020-09-02

Last Posted Date: 2024-10-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT04535401

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 7 locations

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 1

Active, not recruiting

Conditions: Stage III Hypopharyngeal Carcinoma AJCC v8
Advanced Hypopharyngeal Squamous Cell Carcinoma
Advanced Laryngeal Squamous Cell Carcinoma
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage IVA Hypopharyngeal Carcinoma AJCC v8
Advanced Oral Cavity Squamous Cell Carcinoma
Advanced Oropharyngeal Squamous Cell Carcinoma
Advanced Head and Neck Squamous Cell Carcinoma
Stage IVA Lip and Oral Cavity Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Drug: Peposertib
Procedure: Positron Emission Tomography

First Posted Date: 2020-09-01

Last Posted Date: 2025-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT04533750

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 24 locations

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2

Active, not recruiting

Conditions: Localized Prostate Carcinoma
Prostate Adenocarcinoma
Stage I Prostate Cancer AJCC v8
Stage II Prostate Cancer AJCC v8

Interventions: Drug: Apalutamide
Procedure: Biospecimen Collection
Other: Quality-of-Life Assessment

First Posted Date: 2020-08-28

Last Posted Date: 2025-01-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT04530552

Locations: 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States

and more 2 locations

Home Terms & Conditions Privacy Policy